Aaron Miller, M.D..
Dr. Miller is Professor of Neurology and Medical Director Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY.
Within the past 12 months, Dr. Miller has received research support from Acorda, Novartis, Genentech, Genzyme, Sanofi-Avenits, Biogen Idec, Roche and Questor and been a consultant to Genzyme, Sanofi-Aventis, Biogen Idec, Glaxo Smith Kline, EMD Serono, Novartis, Accorda, Nuron Biotech, Accordant Health Services and Teva.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.
This activity is certified for neurology and primary care (internal medicine, family practice and women’s health) and for all health professionals interested in the treatment of RRMS.
This activity is made possible by an unrestricted educational grant from Biogen Idec.
Release Date: 06/02/2014
Upon completion of this Cyberounds®, you should be able to:
Discuss the pathogenesis, epidemiology, symptoms and diagnosis of RRMS
Select and prescribe appropriate pharmaceuticals for patients with RRMS
Discuss the role of risk stratification (e.g., serum JC virus antibody status) in the therapeutic management of RRMS
Describe on-going clinical trials for emerging RRMS therapies/strategies and evaluate data on safety, efficacy and management of side effects.
